Exclusive: Moderna RSV Vaccine Trial in Babies Linked to Severe RSV, Other Serious Injuries
Moderna halted its clinical trial for two experimental infant RSV vaccines in July 2024 after higher severe RSV rates in vaccinated babies. U.K. regulators reported 13 serious adverse reactions. Researchers found lung inflammation in preclinical data, suggesting Moderna downplayed safety signals. The FDA approved the trial without consulting advisers, raising oversight questions. Moderna extended the trial's end date to 2029, delaying final outcome reports.
How this was made
The 30-second read
Why it matters
Safety setbacks raise immediate downside risk; regulatory scrutiny may affect pipeline timelines and investor confidence.
Market read
Primary biotech news with direct impact on Moderna's share price and potential ripple to the sector.
What to watch
Potential for Moderna to pivot to alternative indications or leverage mRNA platform elsewhere.
Background
Moderna's RSV vaccine program faced a halt in 2024 after severe cases; new UK regulator data adds 13 SUSARs and the trial end date was pushed to 2029.
Ticker impact
Moderna's infant RSV vaccine trial was halted after severe RSV cases and new UK SUSAR reports, extending the trial to 2029.
downward pressure as market prices in safety setbacks and regulatory scrutiny
First disclosure of additional SUSARs and trial extension signals deeper safety issues, prompting sell pressure.
Market effects
May dampen sentiment for other RSV vaccine developers and broader biotech safety outlook.
US biotech stocks could see modest declines; UK regulator actions highlight cross‑border oversight.
Limited to biotech sector; no broad market impact.
Counterpoint
If the trial data ultimately prove manageable, the stock could rebound on long‑term vaccine potential.
Key entities
- CompanyModerna
Biotech firm developing mRNA RSV vaccines.
- RegulatorFDA
US agency that approved and later halted the trial.
- RegulatorMHRA
UK regulator providing SUSAR data.
